Home Uncategorized

Uncategorized

Latest

atai Life Sciences Announces First Subject Dosed in the Phase 1 IV-to-Subcutaneous Bridging Study of PCN-101 (R-Ketamine)

atai Life Sciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Pipeline Highlights

atai Life Sciences Reports First Quarter 2023 Financial Results and Announces Pipeline Highlights and Updates

atai Life Sciences to Participate in Upcoming May Investor Conference

atai Life Sciences Presents Pharmacodynamic Data on GRX-917 in a Late Breaking Poster Presentation at the 2023 SOBP Annual Meeting

atai Life Sciences Announces Key Clinical Pipeline and Corporate Updates

atai Life Sciences to Participate in the Cowen 43rd Annual Health...

Expanding ketamine’s horizons for rare neurological disorders

atai Life Sciences Company GABA Therapeutics Announces Positive Final Results from...

atai Life Sciences Announces Results from Phase 2a Trial of PCN-101...

atai Life Sciences Announces Results from the Kures Therapeutics Phase 1...

atai Life Sciences Initiates Phase 2b proof-of-concept trial of RL-007 for...

The atai Fellowship Fund in Psychedelic Neuroscience Announces its First Cohort...

atai Life Sciences Reports Third Quarter 2022 Financial Results and Business...

atai Life Sciences Strengthens Leadership Team with Appointment of Dr. Sahil...

12 3...11 Page 1 of 11

BREAKING: State of Kentucky Sets aside $42 Million for Psychedelic Research,...

Algernon Pharmaceuticals Receives Notice of Allowance from the Japanese Patent Office...

COMPASS Pathways’ Co-Founder Ekaterina Malievskaia to Step Down as Chief Innovation...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

William Leonard Pickard participating in celebration for Sasha Shulgin’s new book...

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.